Abstract
Background: 2'-deoxycytidine (Dcyd) is one of four major nucleosides found in the different normal body fluids due to dissolution of dead cells, and is increase in the presence of malignancy. Previous studies proved that it can be used as a marker for bladder cancer and acute lymphoblastic leukemia. The aim of this study is to assess 2'Dcyd as a possible biological marker in hepatocellular carcinoma (HCC). Methods: Four groups were evaluated for the level 2'-Dcyd as well as alpha-fetoprotein (AFP); a control group (n = 20), 20 cases of chronic liver diseases (CLD), 20 cases of hepatitis C (HCV) 60 cases of HCC. Results: In the patients with HCC, 2'-Dcyd serum level was 8-fold higher than normal level. It was 3-fold higher in HCV group. A mild increase was noted in patients with chronic liver diseases. Levels ≥ 0.14 of 2'-Dcyd had a sensitivity of 93% and specificity of 90% for diagnosis of HCC. It also recorded a sensitivity and specificity of 90% for diagnosis of HCV. Conclusions: For diagnosis of HCC, 2'-Dcyd is no better than AFP, as it is elevated in viral hepatitis C. A combination of AFP and 2'-Dcyd could provide broader information in diagnosis and treatment decision.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
